Telemark Asset Management LLC Invests $12.92 Million in Moderna, Inc. $MRNA

Telemark Asset Management LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the third quarter, Holdings Channel reports. The fund bought 500,000 shares of the company’s stock, valued at approximately $12,915,000. Moderna comprises about 1.2% of Telemark Asset Management LLC’s investment portfolio, making the stock its 27th biggest position.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Moderna in the 2nd quarter valued at about $94,910,000. Federated Hermes Inc. lifted its position in Moderna by 364.5% during the second quarter. Federated Hermes Inc. now owns 2,869,271 shares of the company’s stock valued at $79,163,000 after buying an additional 2,251,497 shares in the last quarter. Geode Capital Management LLC grew its stake in Moderna by 19.1% during the second quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock worth $244,458,000 after buying an additional 1,420,690 shares during the period. Vanguard Group Inc. increased its position in shares of Moderna by 3.2% in the second quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock worth $1,150,743,000 after acquiring an additional 1,312,192 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Moderna by 20.7% in the 2nd quarter. Invesco Ltd. now owns 7,101,032 shares of the company’s stock valued at $195,917,000 after acquiring an additional 1,217,408 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the sale, the director directly owned 3,924 shares of the company’s stock, valued at $115,679.52. The trade was a 85.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.90% of the stock is currently owned by corporate insiders.

Moderna Stock Up 0.3%

Shares of Moderna stock opened at $49.87 on Friday. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $55.20. The company has a market capitalization of $19.49 billion, a PE ratio of -6.86 and a beta of 1.32. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.29 and a quick ratio of 3.22. The business has a 50-day moving average of $39.02 and a 200-day moving average of $30.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.79) by $0.68. The business had revenue of $678.00 million during the quarter, compared to analyst estimates of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The business’s revenue was down 33.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.91) earnings per share. As a group, equities analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MRNA. Piper Sandler reaffirmed an “overweight” rating on shares of Moderna in a research report on Monday, December 1st. TD Cowen restated a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Evercore set a $35.00 target price on Moderna in a report on Tuesday. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a research report on Monday, January 5th. Finally, UBS Group restated a “neutral” rating and issued a $36.00 price target on shares of Moderna in a report on Monday, February 16th. Two equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $31.47.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA will review Moderna’s mRNA flu vaccine application after an initial refusal-to-file, with regulators now targeting a decision by Aug. 5, 2026 — a reversal that boosts the commercial outlook for a new recurring vaccine market and spurred an earlier jump in the stock. Moderna Stock Jumps After FDA Reverses Course on Flu Shot
• Positive Sentiment: Goldman Sachs analyst flagged upside for MRNA, an institutional vote of confidence that can support sentiment and buying interest. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna will present at TD Cowen and Barclays healthcare conferences in March — routine investor access that may provide more management detail but is unlikely by itself to move the stock dramatically. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech sued Moderna in Delaware federal court alleging Moderna’s mNexspike infringes a patent tied to BioNTech/Pfizer’s Comirnaty—new litigation increases legal risk, potential damages or injunctions, and heightens competitive/legal uncertainty for Moderna’s COVID-19/respiratory vaccine portfolio. BioNTech sues Moderna for patent infringement over COVID-19 shots
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in its patent dispute with Arbutus, representing another legal setback that could increase exposure and costs from long-running mRNA technology litigation. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.